| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Zhejiang Xianju Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.15 |
| 52 Week High | CN¥13.57 |
| 52 Week Low | CN¥8.44 |
| Beta | -0.32 |
| 11 Month Change | -8.31% |
| 3 Month Change | 11.50% |
| 1 Year Change | -13.70% |
| 33 Year Change | -8.15% |
| 5 Year Change | 67.42% |
| Change since IPO | 25.25% |
Recent News & Updates
Shareholder Returns
| 002332 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.9% | -0.1% | 0.4% |
| 1Y | -13.7% | -15.9% | -17.8% |
Return vs Industry: 002332 exceeded the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 002332 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
| 002332 volatility | |
|---|---|
| 002332 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002332 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002332's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 3,281 | Weihua Jin | www.xjpharma.com |
Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; and active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progesterone, non-hormone series, newchem API, and intermediates products.
Zhejiang Xianju Pharmaceutical Co.,Ltd. Fundamentals Summary
| 002332 fundamental statistics | |
|---|---|
| Market cap | CN¥11.03b |
| Earnings (TTM) | CN¥581.09m |
| Revenue (TTM) | CN¥4.20b |
19.0x
P/E Ratio2.6x
P/S RatioIs 002332 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002332 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.20b |
| Cost of Revenue | CN¥1.98b |
| Gross Profit | CN¥2.22b |
| Other Expenses | CN¥1.64b |
| Earnings | CN¥581.09m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | 0.59 |
| Gross Margin | 52.87% |
| Net Profit Margin | 13.82% |
| Debt/Equity Ratio | 3.3% |
How did 002332 perform over the long term?
See historical performance and comparison